Auranofin: Repurposing an Old Drug for a Golden New Age

Drugs in R and D

Volumn 15, Issue 1, 2015, Pages 13-20

  Roder, Christine ^a   Thomson, Melanie J ^a  

^a DEAKIN UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AURANOFIN; BAFETINIB; BCR ABL PROTEIN; BENZNIDAZOLE; BORTEZOMIB; CISPLATIN; IMATINIB; INTERLEUKIN 6; INTERLEUKIN 8; MELARSOPROL; MOLYBDENUM; NIFURTIMOX; PRAZIQUANTEL; REACTIVE OXYGEN METABOLITE; SELENIUM; SELENOPROTEIN; THIOREDOXIN REDUCTASE; URIC ACID; VANCOMYCIN; XANTHINE DEHYDROGENASE; ANTIRHEUMATIC AGENT;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ALZHEIMER DISEASE; ANTIINFLAMMATORY ACTIVITY; ANTIPROLIFERATIVE ACTIVITY; APOPTOSIS; ARTICLE; BACTERIAL INFECTION; BIOFILM; BLOOD BRAIN BARRIER; CELL PROLIFERATION; CHAGAS DISEASE; CHEMICAL STRUCTURE; CYTOKINE RELEASE; CYTOTOXICITY; DEGENERATIVE DISEASE; DOSE RESPONSE; ENTEROCOCCUS FAECALIS; GENE EXPRESSION; GROWTH INHIBITION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEISHMANIASIS; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MISSENSE MUTATION; NEOPLASM; NONHUMAN; OXIDATION; OXIDATIVE STRESS; PARASITOSIS; PARKINSON DISEASE; PEPTOCLOSTRIDIUM DIFFICILE; PRIORITY JOURNAL; PROTEIN DEGRADATION; RHEUMATOID ARTHRITIS; TREPONEMA DENTICOLA; VANCOMYCIN RESISTANT ENTEROCOCCUS; DRUG EFFECTS; DRUG REPOSITIONING; METABOLISM; OXIDATION REDUCTION REACTION;

ANTIRHEUMATIC AGENTS; APOPTOSIS; AURANOFIN; DRUG REPOSITIONING; HUMANS; OXIDATION-REDUCTION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES;

EID: 84925498076     PISSN: 11745886     EISSN: 11796901     Source Type: Journal    
DOI: 10.1007/s40268-015-0083-y     Document Type: Article

References (43)

1. Pessetto ZY, Weir SJ, Sethi G, Broward MA, Godwin AK. Drug repurposing for gastrointestinal stromal tumor. Mol Cancer Ther. 2013;12(7):1299–309. doi:10.1158/1535-7163.mct-12-0968.
2. Woodcock J, Woosley R. The FDA critical path initiative and its influence on new drug development. Annu Rev Med. 2008;59:1–12.
3. Tejman-Yarden N, Miyamoto Y, Leitsch D, Santini J, Debnath A, Gut J, et al. A reprofiled drug, auranofin, is effective against metronidazole-resistant Giardia lamblia. Antimicrob Agents Chemother. 2013;57(5):2029–35.
4. Sannella AR, Casini A, Gabbiani C, Messori L, Bilia AR, Vincieri FF, et al. New uses for old drugs. Auranofin, a clinically established antiarthritic metallodrug, exhibits potent antimalarial effects in vitro: mechanistic and pharmacological implications. FEBS Lett. 2008;582(6):844–7.
5. Madeira JM, Renschler CJ, Mueller B, Hashioka S, Gibson DL, Klegeris A. Novel protective properties of auranofin: inhibition of human astrocyte cytotoxic secretions and direct neuroprotection. Life Sci. 2013;92(22):1072–80.
6. Messori L, Marcon G. Gold complexes in the treatment of rheumatoid arthritis. Met Ions Biol Syst. 2004;41:279–304.
7. Kean WF, Kean IR. Clinical pharmacology of gold. Inflammopharmacology. 2008;16(3):112–25.
8. Kean WF, Hart L, Buchanan WW. Auranofin. Br J Rheumatol. 1997;36(5):560–72.
9. Madeira JM, Bajwa E, Stuart MJ, Hashioka S, Klegeris A. Gold drug auranofin could reduce neuroinflammation by inhibiting microglia cytotoxic secretions and primed respiratory burst. J Neuroimmunol. 2014;276(1–2):71–9.
10. Walz DT, DiMartino MJ, Griswold DE, Intoccia AP, Flanagan TL. Biologic actions and pharmacokinetic studies of auranofin. Am J Med. 1983;75(6A):90–108.
11. Doan T, Massarotti E. Rheumatoid arthritis: an overview of new and emerging therapies. J Clin Pharmacol. 2005;45(7):751–62.
12. Behrens R, Devereaux M, Hazleman B, Szaz K, Calvin J, Neale G. Investigation of auranofin-induced diarrhoea. Gut. 1986;27(1):59–65.
13. Ammon HV, Fowle SA, Cunningham JA, Komorowski RA, Loeffler RF. Effects of auranofin and myochrysine on intestinal transport and morphology in the rat. Gut. 1987;28(7):829–34.
14. Fan C, Zheng W, Fu X, Li X, Wong YS, Chen T. Enhancement of auranofin-induced lung cancer cell apoptosis by selenocystine, a natural inhibitor of TrxR1 in vitro and in vivo. Cell Death Dis. 2014;5:e1191.
15. Fiskus W, Saba N, Shen M, Ghias M, Liu J, Gupta SD, et al. Auranofin induces lethal oxidative and endoplasmic reticulum stress and exerts potent preclinical activity against chronic lymphocytic leukemia. Cancer Res. 2014;74(9):2520–32.
16. Marzano C, Gandin V, Folda A, Scutari G, Bindoli A, Rigobello MP. Inhibition of thioredoxin reductase by auranofin induces apoptosis in cisplatin-resistant human ovarian cancer cells. Free Radic Biol Med. 2007;42(6):872–81.
17. Sharlow ER, Leimgruber S, Murray S, Lira A, Sciotti RJ, Hickman M, et al. Auranofin is an apoptosis-simulating agent with in vitro and in vivo anti-leishmanial activity. ACS Chem Biol. 2014;9(3):663–72.
18. Debnath A, Ndao M, Reed SL. Reprofiled drug targets ancient protozoans. Gut Microbes. 2013;4(1):66–71.
19. Ilari A, Baiocco P, Messori L, Fiorillo A, Boffi A, Gramiccia M, et al. A gold-containing drug against parasitic polyamine metabolism: the X-ray structure of trypanothione reductase from Leishmania infantum in complex with auranofin reveals a dual mechanism of enzyme inhibition. Amino Acids. 2012;42(2–3):803–11.
20. Watkins RR, Eckmann L. Treatment of giardiasis: current status and future directions. Curr Infect Dis Rep. 2014;16(2):396.
21. Chirullo B, Sgarbanti R, Limongi D, Shytaj IL, Alvarez D, Das B, et al. A candidate anti-HIV reservoir compound, auranofin, exerts a selective ‘anti-memory’ effect by exploiting the baseline oxidative status of lymphocytes. Cell Death Dis. 2013;4:e944.
22. Caroli A, Simeoni S, Lepore R, Tramontano A, Via A. Investigation of a potential mechanism for the inhibition of SmTGR by auranofin and its implications for Plasmodium falciparum inhibition. Biochem Biophys Res Commun. 2012;417(1):576–81.
23. Jackson-Rosario S, Cowart D, Myers A, Tarrien R, Levine RL, Scott RA, et al. Auranofin disrupts selenium metabolism in Clostridium difficile by forming a stable Au–Se adduct. J Biol Inorg Chem. 2009;14(4):507–19.
24. Jackson-Rosario S, Self WT. Inhibition of selenium metabolism in the oral pathogen Treponema denticola. J Bacteriol. 2009;191(12):4035–40.
25. Chen X, Shi X, Zhao C, Li X, Lan X, Liu S, et al. Anti-rheumatic agent auranofin induced apoptosis in chronic myeloid leukemia cells resistant to imatinib through both Bcr/Abl-dependent and -independent mechanisms. Oncotarget. 2014;5(19):9118–32.
26. Liu N, Li X, Huang H, Zhao C, Liao S, Yang C, et al. Clinically used antirheumatic agent auranofin is a proteasomal deubiquitinase inhibitor and inhibits tumor growth. Oncotarget. 2014;5(14):5453–71.
27. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.
28. Mirabelli CK, Johnson RK, Sung CM, Faucette L, Muirhead K, Crooke ST. Evaluation of the in vivo antitumor activity and in vitro cytotoxic properties of auranofin, a coordinated gold compound, in murine tumor models. Cancer Res. 1985;45(1):32–9.
29. University of Kansas. Phase I and II study of auranofin in chronic lymphocytic leukemia (CLL). [ClinicalTrials.gov identifier NCT01419691]. US National Institutes of Health, ClinicalTrials.gov. http://clinicaltrials.gov.
30. Barnham KJ, Masters CL, Bush AI. Neurodegenerative diseases and oxidative stress. Nat Rev Drug Discov. 2004;3(3):205–14.
31. Shytaj IL, Chirullo B, Wagner W, Ferrari MG, Sgarbanti R, Corte AD, et al. Investigational treatment suspension and enhanced cell-mediated immunity at rebound followed by drug-free remission of simian AIDS. Retrovirology. 2013;10(1):71.
32. CDC’s neglected tropical disease program. Atlanta: Center for Global Health, Division of Parasitic diseases and Malaria; 2014. http://www.cdc.gov/globalhealth/ntd/resources/ntd_factsheet.pdf. Accessed 2 Feb 2015.
33. Lobanov AV, Gromer S, Salinas G, Gladyshev VN. Selenium metabolism in Trypanosoma: characterization of selenoproteomes and identification of a Kinetoplastida-specific selenoprotein. Nucleic Acids Res. 2006;34(14):4012–24.
34. Bonilla M, Denicola A, Novoselov SV, Turanov AA, Protasio A, Izmendi D, et al. Platyhelminth mitochondrial and cytosolic redox homeostasis is controlled by a single thioredoxin glutathione reductase and dependent on selenium and glutathione. J Biol Chem. 2008;283(26):17898–907.
35. Kuntz AN, Davioud-Charvet E, Sayed AA, Califf LL, Dessolin J, Arner ES, et al. Thioredoxin glutathione reductase from Schistosoma mansoni: an essential parasite enzyme and a key drug target. PLoS Med. 2007;4(6):e206.
36. Andrade RM, Chaparro JD, Capparelli E, Reed SL. Auranofin is highly efficacious against Toxoplasma gondii in vitro and in an in vivo experimental model of acute toxoplasmosis. PLoS Negl Trop Dis. 2014;8(7):e2973.
37. World Health Organisation (WHO). Trypanosomiasis, human African (sleeping sickness). Fact sheet no. 259. 2014. http://www.who.int/mediacentre/factsheets/fs259/en/. Accessed 14 Jan 2015.
38. World Health Organisation (WHO). Chagas disease (American trypanosomiasis). Fact sheet no. 340. 2014. http://www.who.int/mediacentre/factsheets/fs340/en/. Accessed 14 Jan 2015.
39. Infectious Diseases Society of America. Combating antimicrobial resistance: policy recommendations to save lives. Clin Infect Dis. 2011;52(suppl 5):S397–428.
40. Antibiotic resistant threats in the United States. US Department of Health and Human Services, Centers for Disease Control and Prevention. 2013. http://www.cdc.gov/drugresistance/threatreport-2013/pdf/ar-threats-2013-508.pdf. Accessed 27 Nov 2014.
41. Jackson S, Calos M, Myers A, Self WT. Analysis of proline reduction in the nosocomial pathogen Clostridium difficile. J Bacteriol. 2006;188(24):8487–95.
42. Hokai Y, Jurkowicz B, Fernandez-Gallardo J, Zakirkhodjaev N, Sanau M, Muth TR, et al. Auranofin and related heterometallic gold(I)-thiolates as potent inhibitors of methicillin-resistant Staphylococcus aureus bacterial strains. J Inorg Biochem. 2014;138C:81–8.
43. Srivastava M, Mallard C, Barke T, Hancock LE, Self WT. A selenium-dependent xanthine dehydrogenase triggers biofilm proliferation in Enterococcus faecalis through oxidant production. J Bacteriol. 2011;193(7):1643–52.